Innovating Works

OPTIMATA

Desconocido
COLOSSUS: Advancing a Precision Medicine Paradigm in metastatic Colorectal Cancer Systems based patient stra... Optimata ltd. participó en un H2020: H2020-SC1-2016-2017 Colorectal cancer (CRC) is the third most common cancer in Europe with c. 420,000 cases and 150,000 related deaths in 2012. Of total CRC cas...
2017-11-21 - 2023-06-30 | Financiado
TRAIN-ERS: Endoplasmic Reticulum Stress in Health and Disease Optimata ltd. participó en un H2020: H2020-MSCA-ITN-2015 Endoplasmic reticulum (ER) stress is emerging as a common feature in the pathology of numerous diseases including cancer, neurodegenerative...
2015-08-18 - 2019-09-30 | Financiado
MEL-PLEX: Exploiting MELanoma disease comPLEXity to address European research training needs in translational... Optimata ltd. participó en un H2020: H2020-MSCA-ITN-2014 Novel treatment options and associated personalised, patient-tailored therapies need to be explored and developed for highly heterogeneous a...
2014-12-16 - 2018-11-30 | Financiado
DDMORE: Drug Disease Model Resources Optimata ltd. participó en un FP6: Model based-drug development (MBDD) is accepted as a vital approach in understanding patient risk/benefit and attrition. At the core of MBDD...
2011-03-01 - 2016-08-31 | Financiado
DDMORE: Drug Disease Model Resources Optimata ltd. participó en un FP7: Model based-drug development (MBDD) is accepted as a vital approach in understanding patient risk/benefit and attrition. At the core of MBDD...
Financiado
APO-DECIDE: Apoptosis Modelling for Treatment Decisions in Colorectal Cancer Optimata ltd. participó en un FP7: "With the arrival of new colorectal cancer (CRC) therapeutics targeting specific cell signalling pathways, such as anti-EGFR therapy, person...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.